Challenges and advances in pathological assessment after neoadjuvant therapy for pancreatic cancer
10.3760/cma.j.cn113855-20240313-00190
- VernacularTitle:胰腺癌新辅助治疗后病理评估的挑战和研究进展
- Author:
Lingyu ZHU
1
;
Hui JIANG
;
Shiwei GUO
;
Gang JIN
Author Information
1. 海军军医大学第一附属医院胰腺肝胆外科，上海 200433
- Publication Type:Journal Article
- Keywords:
Pathology,surgical;
Pancreatic neoplasms;
Neoadjuvant therapy;
Pathological assessment;
Sampling;
Resection margin
- From:
Chinese Journal of General Surgery
2025;40(3):183-187
- CountryChina
- Language:Chinese
-
Abstract:
Integrative management for pancreatic cancer has stepped into the neoadjuvant era, which brings new issues and challenges for pathological evaluation of surgical specimens. Given the absence of standardized guidelines for the pathological examination and reporting of resected specimens of pancreatic cancer after neoadjuvant therapy, there are variations in pathology sampling, tumor regression grade assessment, and margin assessment between institutions, which substantially impairs the comparability of results between studies. This review provides evidence-based opinions and references for clinical diagnosis and management through sorting out the controversies and difficulties in the assessment of the above pathological parameters after neoadjuvant therapy for pancreatic cancer.
